GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients : The AMYPAD-DPMS Randomized Clinical Trial
    American Medical Association (AMA) ; 2023
    In:  JAMA Neurology Vol. 80, No. 6 ( 2023-06-01), p. 548-
    Details
    In: JAMA Neurology, American Medical Association (AMA), Vol. 80, No. 6 ( 2023-06-01), p. 548-
    Abstract: Amyloid positron emission tomography (PET) allows the direct assessment of amyloid deposition, one of the main hallmarks of Alzheimer disease. However, this technique is currently not widely reimbursed because of the lack of appropriately designed studies demonstrating its clinical effect. Objective To assess the clinical effect of amyloid PET in memory clinic patients. Design, Setting, and Participants The AMYPAD-DPMS is a prospective randomized clinical trial in 8 European memory clinics. Participants were allocated (using a minimization method) to 3 study groups based on the performance of amyloid PET: arm 1, early in the diagnostic workup (within 1 month); arm 2, late in the diagnostic workup (after a mean [SD] 8 [2] months); or arm 3, if and when the managing physician chose. Participants were patients with subjective cognitive decline plus (SCD+; SCD plus clinical features increasing the likelihood of preclinical Alzheimer disease), mild cognitive impairment (MCI), or dementia; they were assessed at baseline and after 3 months. Recruitment took place between April 16, 2018, and October 30, 2020. Data analysis was performed from July 2022 to January 2023. Intervention Amyloid PET. Main Outcome and Measure The main outcome was the difference between arm 1 and arm 2 in the proportion of participants receiving an etiological diagnosis with a very high confidence (ie, ≥90% on a 50%-100% visual numeric scale) after 3 months. Results A total of 844 participants were screened, and 840 were enrolled (291 in arm 1, 271 in arm 2, 278 in arm 3). Baseline and 3-month visit data were available for 272 participants in arm 1 and 260 in arm 2 (median [IQR] age: 71 [65-77] and 71 [65-77] years; 150/272 male [55%] and 135/260 male [52%]; 122/272 female [45%] and 125/260 female [48%]; median [IQR] education: 12 [10-15] and 13 [10-16] years, respectively). After 3 months, 109 of 272 participants (40%) in arm 1 had a diagnosis with very high confidence vs 30 of 260 (11%) in arm 2 ( P   & amp;lt; .001). This was consistent across cognitive stages (SCD+: 25/84 [30%] vs 5/78 [6%] ; P   & amp;lt; .001; MCI: 45/108 [42%] vs 9/102 [9%] ; P   & amp;lt; .001; dementia: 39/80 [49%] vs 16/80 [20%] ; P   & amp;lt; .001). Conclusion and Relevance In this study, early amyloid PET allowed memory clinic patients to receive an etiological diagnosis with very high confidence after only 3 months compared with patients who had not undergone amyloid PET. These findings support the implementation of amyloid PET early in the diagnostic workup of memory clinic patients. Trial Registration EudraCT Number: 2017-002527-21
    Type of Medium: Online Resource
    ISSN: 2168-6149
    URL: Article
    DOI: 10.1001/jamaneurol.2023.0997
    Language: English
    Publisher: American Medical Association (AMA)
    Publication Date: 2023
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Analysis of Psychological Symptoms Following Disclosure of Amyloid–Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline
    American Medical Association (AMA) ; 2023
    In:  JAMA Network Open Vol. 6, No. 1 ( 2023-01-13), p. e2250921-
    Details
    In: JAMA Network Open, American Medical Association (AMA), Vol. 6, No. 1 ( 2023-01-13), p. e2250921-
    Abstract: Individuals who are amyloid-positive with subjective cognitive decline and clinical features increasing the likelihood of preclinical Alzheimer disease (SCD+) are at higher risk of developing dementia. Some individuals with SCD+ undergo amyloid-positron emission tomography (PET) as part of research studies and frequently wish to know their amyloid status; however, the disclosure of a positive amyloid-PET result might have psychological risks. Objective To assess the psychological outcomes of the amyloid-PET result disclosure in individuals with SCD+ and explore which variables are associated with a safer disclosure in individuals who are amyloid positive. Design, Setting, and Participants This prospective, multicenter study was conducted as part of The Amyloid Imaging to Prevent Alzheimer Disease Diagnostic and Patient Management Study (AMYPAD-DPMS) (recruitment period: from April 2018 to October 2020). The setting was 5 European memory clinics, and participants included patients with SCD+ who underwent amyloid-PET. Statistical analysis was performed from July to October 2022. Exposures Disclosure of amyloid-PET result. Main Outcomes and Measures Psychological outcomes were defined as (1) disclosure related distress, assessed using the Impact of Event Scale–Revised (IES-R; scores of at least 33 indicate probable presence of posttraumatic stress disorder [PTSD]); and (2) anxiety and depression, assessed using the Hospital Anxiety and Depression scale (HADS; scores of at least 15 indicate probable presence of severe mood disorder symptoms). Results After disclosure, 27 patients with amyloid-positive SCD+ (median [IQR] age, 70 [66-74] years; gender: 14 men [52%]; median [IQR] education: 15 [13 to 17] years, median [IQR] Mini-Mental State Examination [MMSE] score, 29 [28 to 30] ) had higher median (IQR) IES-R total score (10 [2 to 14] vs 0 [0 to 2] ; P   & amp;lt; .001), IES-R avoidance (0.00 [0.00 to 0.69] vs 0.00 [0.00 to 0.00] ; P   & amp;lt; .001), IES-R intrusions (0.50 [0.13 to 0.75] vs 0.00 [0.00 to 0.25] ; P   & amp;lt; .001), and IES-R hyperarousal (0.33 [0.00 to 0.67] vs 0.00 [0.00 to 0.00] ; P   & amp;lt; .001) scores than the 78 patients who were amyloid-negative (median [IQR], age, 67 [64 to 74] years, 45 men [58%], median [IQR] education: 15 [12 to 17] years, median [IQR] MMSE score: 29 [28 to 30]). There were no observed differences between amyloid-positive and amyloid-negative patients in the median (IQR) HADS Anxiety (–1.0 [–3.0 to 1.8] vs –2.0 [–4.8 to 1.0]; P  = .06) and Depression (–1.0 [–2.0 to 0.0] vs –1.0 [–3.0 to 0.0] ; P  = .46) deltas (score after disclosure – scores at baseline). In patients with amyloid-positive SCD+, despite the small sample size, higher education was associated with lower disclosure-related distress (ρ = –0.43; P  = .02) whereas the presence of study partner was associated with higher disclosure-related distress ( W  = 7.5; P  = .03). No participants with amyloid-positive SCD+ showed probable presence of PTSD or severe anxiety or depression symptoms at follow-up. Conclusions and Relevance The disclosure of a positive amyloid-PET result to patients with SCD+ was associated with a bigger psychological change, yet such change did not reach the threshold for clinical concern.
    Type of Medium: Online Resource
    ISSN: 2574-3805
    URL: Article
    DOI: 10.1001/jamanetworkopen.2022.50921
    Language: English
    Publisher: American Medical Association (AMA)
    Publication Date: 2023
    detail.hit.zdb_id: 2931249-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Inverse relationship between education and amyloid burden in individuals with subjective cognitive decline plus and mild cognitive impairment
    Wiley ; 2023
    In:  Alzheimer's & Dementia Vol. 19, No. S3 ( 2023-06)
    Details
    In: Alzheimer's & Dementia, Wiley, Vol. 19, No. S3 ( 2023-06)
    Abstract: Higher educated patients with MCI can tolerate more neuropathology than lower educated patients with similar clinical impairment. It is not known whether this observation also accounts for potential preclinical stages of AD, namely subjective cognitive decline plus (SCD+). Method Data of 197 SCD+ individuals, 227 MCI and 157 AD patients were included, which were collected as part of the AMYPAD‐DPMS cohort (https://amypad.eu/). First, median education in years was computed across the AD‐spectrum groups for each of the 8 European sites. Next, using a median split, the SCD+, MCI and AD cohort were separately categorized into a higher and lower educated group, excluding subjects with median education. Afterwards, the higher and lower educated AD‐spectrum groups were matched for age, sex and cognitive function (MMSE) using propensity score matching in R, leading to the following sample (low/high education): 54/54 SCD+, 70/81 MCI and 56/65 AD patients. Global amyloid load was compared between education groups using Centiloid (CL) information derived from Flutemetamol and Florbetaben PET scans. To confirm the results of the stringent group comparison, partial correlations between years of education and CL values correcting for age, sex and tracer type were performed for each AD‐spectrum group. All analyses were conducted in SPSS 28 and significance level was set to p 〈 .05. Result Higher educated SCD+ subjects presented significantly (p 〈 . 001) lower CL values (M(CL) = 16.48) than lower educated SCD+ subjects (M(CL) = 32.17), whereas the opposite effect (p 〈 .046) was observed in the MCI cohort with higher educated MCI patients presenting greater CL values (M(CL) = 57.08) compared to the lower educated MCI group (M(CL) = 41.74). No difference was found in the AD group. Results were further confirmed by the correlation approach across the unmatched sample yielding a negative association between years of education and CL values in the SCD+ group (r = ‐.159, p = .027) and a positive association in the MCI group (r = .153, p = .022). Conclusion These results indicate that sensitivity to early amyloid accumulation may possibly increase with higher education in potential preclinical stages of AD, whereas in clinical stages of AD higher education may support compensatory mechanisms against amyloid burden.
    Type of Medium: Online Resource
    ISSN: 1552-5260 , 1552-5279
    URL: Issue
    URL: Article
    DOI: 10.1002/alz.v19.S3
    DOI: 10.1002/alz.064097
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2201940-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study
    Wiley ; 2020
    In:  Alzheimer's & Dementia Vol. 16, No. 5 ( 2020-05), p. 750-758
    Details
    In: Alzheimer's & Dementia, Wiley, Vol. 16, No. 5 ( 2020-05), p. 750-758
    Abstract: The Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) Prognostic and Natural History Study (PNHS) aims at understanding the role of amyloid imaging in the earliest stages of Alzheimer's disease (AD). AMYPAD PNHS adds (semi‐)quantitative amyloid PET imaging to several European parent cohorts (PCs) to predict AD‐related progression as well as address methodological challenges in amyloid PET. Methods AMYPAD PNHS is an open‐label, prospective, multi‐center, cohort study recruiting from multiple PCs. Around 2000 participants will undergo baseline amyloid positron emission tomography (PET), half of whom will be invited for a follow‐up PET 12 at least 12 months later. Results Primary include several amyloid PET measurements (Centiloid, SUVr, BP ND , R 1 ), and secondary are their changes from baseline, relationship to other amyloid markers (cerebrospinal fluid and visual assessment), and predictive value of AD‐related decline. Expected Impact Determining the role of amyloid PET for the understanding of this complex disease and potentially improving secondary prevention trials.
    Type of Medium: Online Resource
    ISSN: 1552-5260 , 1552-5279
    URL: Issue
    URL: Article
    DOI: 10.1002/alz.v16.5
    DOI: 10.1002/alz.12069
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2201940-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    AMYPAD Diagnostic and Patient Management Study: Rationale and design
    Wiley ; 2019
    In:  Alzheimer's & Dementia Vol. 15, No. 3 ( 2019-03), p. 388-399
    Details
    In: Alzheimer's & Dementia, Wiley, Vol. 15, No. 3 ( 2019-03), p. 388-399
    Abstract: Reimbursement of amyloid–positron emission tomography (PET) is lagging due to the lack of definitive evidence on its clinical utility and cost‐effectiveness. The Amyloid Imaging to Prevent Alzheimer's Disease–Diagnostic and Patient Management Study (AMYPAD‐DPMS) is designed to fill this gap. Methods AMYPAD‐DPMS is a phase 4, multicenter, prospective, randomized controlled study. Nine hundred patients with subjective cognitive decline plus, mild cognitive impairment, and dementia possibly due to Alzheimer's disease will be randomized to ARM1, amyloid‐PET performed early in the diagnostic workup; ARM2, amyloid‐PET performed after 8 months; and ARM3, amyloid‐PET performed whenever the physician chooses to do so. Endpoints The primary endpoint is the difference between ARM1 and ARM2 in the proportion of patients receiving a very‐high‐confidence etiologic diagnosis after 3 months. Secondary endpoints address diagnosis and diagnostic confidence, diagnostic/therapeutic management, health economics and patient‐related outcomes, and methods for image quantitation. Expected Impacts AMYPAD‐DPMS will supply physicians and health care payers with real‐world data to plan management decisions.
    Type of Medium: Online Resource
    ISSN: 1552-5260 , 1552-5279
    URL: Article
    DOI: 10.1016/j.jalz.2018.09.003
    Language: English
    Publisher: Wiley
    Publication Date: 2019
    detail.hit.zdb_id: 2201940-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Impact of the disclosure of amyloid‐PET results to patients with subjective cognitive decline: the AMYPAD Diagnostic and Patient Management Study (DPMS) : Neuroimaging / Normal brain aging
    Wiley ; 2020
    In:  Alzheimer's & Dementia Vol. 16, No. S5 ( 2020-12)
    Details
    In: Alzheimer's & Dementia, Wiley, Vol. 16, No. S5 ( 2020-12)
    Abstract: Amyloid‐PET is increasingly used for diagnostic purposes in patients with cognitive impairment due to suspected Alzheimer’s disease. However, cognitively unimpaired individuals are frequently included in research studies involving amyloid‐PET scan. Even if amyloid‐PET is not clinically recommended in these cases, these patients often want to know their amyloid status, a strong risk factor for incident dementia. Currently, evidence on the impact of the disclosure of amyloid‐PET results on patients’ psychological well‐being is scanty. The aim of this sub‐study is to assess how a positive amyloid‐PET result affects the psychological well‐being of patients with subjective cognitive decline plus (SCD+) enrolled in a prospective study on the diagnostic utility of amyloid PET (AMYPAD‐DPMS). Method The impact of the disclosure of amyloid‐PET results on patient’s psychological well‐being was investigated using the Impact of Event Scale–Revised (IES‐R). IES‐R is used to detect potential changes from the current time point and a previous time point preceding up to 7 days an event (the amyloid‐PET result disclosure in this case). IES‐R was administered 1‐3 days post‐disclosure, and consists of one total score (0‐88) and three sub‐scores (0‐4): avoidance (avoidance of thoughts, feelings, memories or situations), intrusions (intrusive memories, thoughts, or feelings causing distress), and hyperarousal (hypervigilance, feeling watchful and on guard, difficulty concentrating). IES‐R total score between 12‐32: symptoms of post‐traumatic stress, patient monitoring is required; ≥33: probable presence of a post‐traumatic stress disorder. Result So far, 36 SCD+ participants of AMYPAD‐DPMS, who received their amyloid‐PET results, have accepted to participate in this sub‐study. Amyloid‐positive patients (n=9) had higher IES‐R total score (median=10, lower‐upper quartiles=1‐14) than amyloid‐negatives (1, 0‐6), albeit at trend level ( p =0.052). We also observed higher avoidance scores in amyloid‐positives compared to amyloid‐negatives (0, 0.00‐0.62 vs. 0, 0.00‐0.00, p =0.004), but no differences in the other two sub‐scores ( p 〉 0.05). Conclusion These preliminary data on 36 participants suggests that the disclosure of positive amyloid scan to an SCD+ patient is associated with the avoidance of thoughts and memories of the news. Future analyses will address additional outcome measures (e.g. post‐disclosure anxiety and depression) and factors associated with a milder psychological impact in amyloid‐positive patients.
    Type of Medium: Online Resource
    ISSN: 1552-5260 , 1552-5279
    URL: Issue
    URL: Article
    DOI: 10.1002/alz.v16.S5
    DOI: 10.1002/alz.040952
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2201940-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    Description of a European memory clinic cohort undergoing amyloid‐PET: The AMYPAD Diagnostic and Patient Management Study
    Wiley ; 2023
    In:  Alzheimer's & Dementia Vol. 19, No. 3 ( 2023-03), p. 844-856
    Details
    In: Alzheimer's & Dementia, Wiley, Vol. 19, No. 3 ( 2023-03), p. 844-856
    Abstract: AMYPAD Diagnostic and Patient Management Study (DPMS) aims to investigate the clinical utility and cost‐effectiveness of amyloid‐PET in Europe. Here we present participants’ baseline features and discuss the representativeness of the cohort. Methods Participants with subjective cognitive decline plus (SCD+), mild cognitive impairment (MCI), or dementia were recruited in eight European memory clinics from April 16, 2018, to October 30, 2020, and randomized into three arms: ARM1, early amyloid‐PET; ARM2, late amyloid‐PET; and ARM3, free‐choice. Results A total of 840 participants (244 SCD+, 341 MCI, and 255 dementia) were enrolled. Sociodemographic/clinical features did not differ significantly among recruiting memory clinics or with previously reported cohorts. The randomization assigned 35% of participants to ARM1, 32% to ARM2, and 33% to ARM3; cognitive stages were distributed equally across the arms. Discussion The features of AMYPAD‐DPMS participants are as expected for a memory clinic population. This ensures the generalizability of future study results.
    Type of Medium: Online Resource
    ISSN: 1552-5260 , 1552-5279
    URL: Issue
    URL: Article
    DOI: 10.1002/alz.v19.3
    DOI: 10.1002/alz.12696
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2201940-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    The use of amyloid‐PET in memory clinic patients: AMYPAD Diagnostic and Patient Management Study
    Wiley ; 2022
    In:  Alzheimer's & Dementia Vol. 18, No. S5 ( 2022-12)
    Details
    In: Alzheimer's & Dementia, Wiley, Vol. 18, No. S5 ( 2022-12)
    Abstract: Amyloid‐PET allows the direct assessment of amyloid deposition, one of the main hallmarks of Alzheimer’s disease. However, this technique is currently not or incompletely reimbursed due to lack of randomized controlled studies demonstrating a clinical impact. Method AMYPAD‐DPMS is a prospective, multicenter, randomized controlled study. Patients with subjective cognitive decline plus (SCD+), mild cognitive impairment (MCI) or dementia from 8 European memory clinics were randomized into three study arms: ARM1, amyloid‐PET performed early in the diagnostic workup (within 1 month); ARM2, late in the diagnostic workup (after 8±2 months); or ARM3, if and when the managing physician chose to. The primary endpoint was the proportional difference in ARM1 and ARM2 participants in receiving an etiological diagnosis with very high diagnostic confidence (i.e. ≥ 90%) within 3 months. Secondary endpoints included changes in diagnosis and treatment plan. Result Participants were recruited from April 16th, 2018, to October 30th, 2020. There were 272 participants in ARM1, 260 ARM2, and 261 ARM3 that underwent both baseline and 3‐month visit. 88% of ARM3 participants underwent amyloid‐PET within 3 months, and the average time from baseline to prescribe amyloid‐PET was 46 (IQR=58) days. After 3 months, 40% (109/272) of ARM1 participants and 37% (97/261) of ARM3 had a diagnosis with very high confidence vs 11% (30/260) in ARM2 (p 〈 0.001). This was consistent across clinical stages (SCD+: 30%, 22%, and 6%, p 〈 0.05; MCI: 42%, 39%, and 9%, p 〈 0.05; dementia: 49%, 49%, and 20%, p 〈 0.05). Changes in diagnosis were more frequent in ARM1 (44%) versus ARM3 (29%, p=0.001) and ARM2 (11%, p 〈 0.001), and in ARM3 versus ARM2 (p 〈 0.001). In participants for whom an etiological diagnosis of AD or non‐AD was confirmed after 3 months, changes in diagnostic confidence were greater in ARM1 (AD: +14%; non‐AD: +12%) and ARM3 (+11%; +10%) vs ARM2 (+1%, +1%; p 〈 0.05). Conclusion An amyloid‐PET performed in the early phases of a diagnostic workup is associated with a greater proportion of etiological diagnoses with very high confidence and more frequent changes in diagnosis and higher diagnostic confidence after 3 months. This evidence supports the implementation of this technique early in the diagnostic workup.
    Type of Medium: Online Resource
    ISSN: 1552-5260 , 1552-5279
    URL: Issue
    URL: Article
    DOI: 10.1002/alz.v18.S5
    DOI: 10.1002/alz.064648
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2201940-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    Quantitative amyloid PET in the AMYPAD diagnostic and patient management study
    Wiley ; 2021
    In:  Alzheimer's & Dementia Vol. 17, No. S5 ( 2021-12)
    Details
    In: Alzheimer's & Dementia, Wiley, Vol. 17, No. S5 ( 2021-12)
    Abstract: AMYPAD‐DPMS is a European, multicenter, prospective, interventional, randomized controlled study. It aims to assess clinical utility and cost‐effectiveness of amyloid‐PET. It recruited individuals with Subjective Cognitive Decline plus (SCD+), and syndromic diagnosis of Mild Cognitive Impairment (MCI) and dementia. Here, we describe the quantitative results of the basal amyloid PET performed in these participants. Method Until end of recruitment on October 30 th , 2020, 844 participants were included in AMYPAD‐DPMS from 8 clinical sites. Of those, 186 are from the Geneva site, 143 from Amsterdam, 130 from Toulouse, 101 from Barcelona, 94 from Cologne, 73 from Stockholm, 64 from London and 53 from Lausanne. Amyloid PET was performed with either 18F‐florbetaben or 18F‐flutemetamol and analysed with AmyPype, a PET‐only Centiloid‐calibrated pipeline running on a GE Advantage Workstation, to render comparable estimates of global amyloid load for both tracers. The standard Global Cortical Average region of interest was used as target region and the whole cerebellum as reference. Distributions as well as Mean and Standard Deviations (SD) of CL values by tracer, site and by diagnostic groups were computed. Result From the 844 recruited participants, 245 (29%) were SCD, 341 (40%) MCI and 258 (31%) dementia. By January 19 th , 2021, 661 scans had been analyzed with AmyPype and had passed quality control. Of them, 308 (47%) were scanned using 18F‐florbetaben and 353 (53%) with 18F‐flutemetamol. The global mean (SD) [range] of Centiloid (CL) values was 45.0 (49.0) [ ‐52.4, 221.9] CL. By clinical group, the average (SD) CL values were 25.5(39.1) for SCD+, 45.8(47.9) for MCI, and 66.3(51.1) for dementia patients. CL distributions by clinical group are shown in Figure 1, and per‐site and tracer in Figures 2‐3 for the MCI and Dementia groups. Conclusion Quantitative amyloid PET in AMYPAD‐DPMS shows a very well‐balanced tracer use. As expected, CL values increased with increasing disease severity. The consistent distribution of the majority of CL values within/across clinical groups suggest that the Centiloid transformation implemented in AmyPype allowed the direct comparison of estimates of amyloid burden across the two tracers used in this trial.
    Type of Medium: Online Resource
    ISSN: 1552-5260 , 1552-5279
    URL: Issue
    URL: Article
    DOI: 10.1002/alz.v17.S5
    DOI: 10.1002/alz.055940
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2201940-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    The amyloid imaging for the prevention of Alzheimer's disease consortium: A European collaboration with global impact
    Frontiers Media SA ; 2023
    In:  Frontiers in Neurology Vol. 13 ( 2023-1-20)
    Details
    In: Frontiers in Neurology, Frontiers Media SA, Vol. 13 ( 2023-1-20)
    Abstract: Amyloid-β (Aβ) accumulation is considered the earliest pathological change in Alzheimer's disease (AD). The Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) consortium is a collaborative European framework across European Federation of Pharmaceutical Industries Associations (EFPIA), academic, and ‘Small and Medium-sized enterprises’ (SME) partners aiming to provide evidence on the clinical utility and cost-effectiveness of Positron Emission Tomography (PET) imaging in diagnostic work-up of AD and to support clinical trial design by developing optimal quantitative methodology in an early AD population. The AMYPAD studies In the Diagnostic and Patient Management Study (DPMS), 844 participants from eight centres across three clinical subgroups (245 subjective cognitive decline, 342 mild cognitive impairment, and 258 dementia) were included. The Prognostic and Natural History Study (PNHS) recruited pre-dementia subjects across 11 European parent cohorts (PCs). Approximately 1600 unique subjects with historical and prospective data were collected within this study. PET acquisition with [ 18 F]flutemetamol or [ 18 F]florbetaben radiotracers was performed and quantified using the Centiloid (CL) method. Results AMYPAD has significantly contributed to the AD field by furthering our understanding of amyloid deposition in the brain and the optimal methodology to measure this process. Main contributions so far include the validation of the dual-time window acquisition protocol to derive the fully quantitative non-displaceable binding potential (BP ND ), assess the value of this metric in the context of clinical trials, improve PET-sensitivity to emerging Aβ burden and utilize its available regional information, establish the quantitative accuracy of the Centiloid method across tracers and support implementation of quantitative amyloid-PET measures in the clinical routine. Future steps The AMYPAD consortium has succeeded in recruiting and following a large number of prospective subjects and setting up a collaborative framework to integrate data across European PCs. Efforts are currently ongoing in collaboration with ARIDHIA and ADDI to harmonize, integrate, and curate all available clinical data from the PNHS PCs, which will become openly accessible to the wider scientific community.
    Type of Medium: Online Resource
    ISSN: 1664-2295
    URL: Article
    DOI: 10.3389/fneur.2022.1063598
    Language: Unknown
    Publisher: Frontiers Media SA
    Publication Date: 2023
    detail.hit.zdb_id: 2564214-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...